In Landmark Study, Immunotherapy Boosts Survival of Advanced Hodgkin Lymphoma
University of Rochester Medical CenterA treatment that rallies the immune system to destroy cancer raised the survival rate for advanced Hodgkin lymphoma patients to a remarkable 92 percent, suggesting a new standard therapy for the disease. The New England Journal of Medicine published the innovative clinical trial results this week.